Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

This is a Phase 1, randomized, open label, 2 treatment, 2 period, 2-way crossover study, with an extension phase design in which the steady state PK of ARQ 197 will be investigated using the tablet administered in fed state (test treatment) and capsule administered at least 1 hour before or 2 hours after a meal (reference treatment) in subjects with advanced solid tumors.

Key facts

Study ID

NCT01149720

Run by

Daiichi Sankyo

People needed

24

Starts

2010-07-01

Expected to finish

2011-03-01

Last updated by the study team

2019-02-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have a histologically or cytologically confirmed advanced solid tumor at screening.
• Male or female equal or greater than 18 years of age.
• All female subjects of childbearing potential must each have a negative serum pregnancy test result before initiating study treatment.
• An Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 2
• Adequate bone marrow, liver, and renal function, defined as:
• Platelet count equal or greater than 75 x 10(9)/L
• Hemoglobin (Hb) equal or greater than 9.0 g/dL
• Absolute neutrophil count (ANC) equal or greater than 1.5 x 10(9)/L
• Total bilirubin equal or less than 1.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal or less than 3 x ULN (equal or less than 5 x ULN for subjects with liver metastases)
• Serum creatinine equal or less than 1.5 x ULN

You may not qualify if…

• History of cardiac disease: Active coronary artery disease (CAD), defined as myocardial infarction (MI), unstable angina, coronary bypass graft (CABG), or stenting within 6 months prior to study entry (an MI that occurred > 6 months prior to study entry is permitted)
• Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0, or uncontrolled hypertension
• Active, clinically serious infection(s) defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0.
• Known metastatic brain or meningeal tumors, unless the subject is > 3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of first dose of study drug.
• Prior therapy with mesenchymal-epithelial transition factor (c-MET) inhibitors, including ARQ 197.

Where it is running

• Premiere Oncology — Santa Monica, California, United States
• Florida Cancer Specialists — Fort Myers, Florida, United States
• Sarah Cannon Research Institute (SCRI) — Nashville, Tennessee, United States
• START - South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.